The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
Open accessAbstract
The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with meta-analysis to assess its possible prognostic value on survival. Published studies on lung cancer assessing prognostic value of RAS mutation or p21 overexpression on survival were identified by an electronic search. After a methodological assessment, we estimated individual hazard ratios (HR) estimating RAS protein alteration or RAS mutation effect on survival and combined them using meta-analytic methods. In total, 53 studies were found eligible, with 10 concerning the same cohorts of patients. Among the 43 remaining studies, the revelation method was immunohistochemistry (IHC) in nine and polymerase chain reaction (PCR) in 34. Results in terms of survival were significantly pejorative, significantly favourable, not significant and not conclusive in 9, 1, 31, 2, respectively. In total, 29 studies were evaluable for meta-analysis but we aggregated only the 28 dealing with non-small-cell lung cancer (NSCLC) and not the only one dealing with small-cell-lung cancer (SCLC). The quality scores were not statistically significantly different between studies with or without significant results in terms of survival, allowing us to perform a quantitative aggregation. The combined HR was 1.35 (95% CI: 1.16-1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26-2.02) and in studies using PCR (HR 1.40; 95% CI 1.18-1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86-1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205 · cited 1×
“The individual HR estimates were combined into an overall HR using Peto’s method (Yusuf et al, 1985), which consisted of using a fixed effect model assuming homogeneity of the individual true HRs.”
MethodK-ras Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderschueren, R. G. J. R. A., van Zandwijk, N., Mooi, W. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230902 · Cited by 809
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582 · cited 2×
“In lung cancer, Fisher et al (2001) has demonstrated that RAS mutation is necessary for induction and maintenance of lung cancer.”
BackgroundInfluentialRodenhuis, S., Slebos, R. J. C., Boot, A. J., Evers, S. G., Mooi, W. J., WAGENAAR, S. S., Bodegom, P. C. V., & Bos, J. L. (1988) · PubMed · Cited by 465
Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, C., Meert, A. P., Vallot, F., Lafitte, J. J., & Sculier, J. P. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00062201 · Cited by 418
Self-citationPaesmans, M., Sculier, J. P., Libert, P., Bureau, G., Dabouis, G., Thiriaux, J., Michel, J., Van Cutsem, O., Sergysels, R., & Mommen, P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1221 · Cited by 386
Self-citationMeert, A.-P., Martin, B., Delmotte, P., Berghmans, T., Lafitte, J.-J., Mascaux, C., Paesmans, M., Steels, E., Verdebout, J.-M., & Sculier, J.-P. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00296502 · Cited by 264
Self-citationMitsudomi, T., Steinberg, S. M., Oie, H. K., Mulshine, J. L., Phelps, R. M., Viallet, J., Pass, H. I., Minna, J. D., & Gazdar, A. F. (1991) · PubMed · Cited by 248
Meert, A.-P., Paesmans, M., Martin, B., Delmotte, P., Berghmans, T., Verdebout, J.-M., Lafitte, J.-J., Mascaux, C., & Sculier, J.-P. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600551 · Cited by 241
Self-citationImplications and Prognostic Value of K-ras Mutation for Early-Stage Lung Cancer in Women
Nelson, H. H., Christiani, D. C., Mark, E. J., Wiencke, J. K., Wain, J. C., & Kelsey, K. T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2032 · Cited by 227
Rodenhuis, S. (1992) · PubMed · Cited by 222
Schiller, J. H., Adak, S., Feins, R. H., Keller, S. M., Fry, W. A., Livingston, R. B., Hammond, M. E. M., Wolf, B., Sabatini, L., Jett, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.448 · Cited by 192
Graziano, S. L., Gamble, G. P., Newman, N. B., Abbott, L. Z., Rooney, M., Mookherjee, S., Lamb, M. L., Kohman, L. J., & Poiesz, B. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.668 · Cited by 191
Kern, J. A., Slebos, R. J., Top, B., Rodenhuis, S., Lager, D., Robinson, R. A., Weiner, D., & Schwartz, D. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117001 · Cited by 182
Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E., Shieh, D. B., Richards, W., Blanco, R., Xu, H. J., Strauss, G. M., & Sugarbaker, D. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2468 · Cited by 178
Huncharek, M. (1999) · Carcinogenesis · doi:10.1093/carcin/20.8.1507 · Cited by 172
Detection of K-ras mutations in lung carcinomas: Relationship to prognosis
(1996) · Lung Cancer · doi:10.1016/s0169-5002(96)80041-9 · Cited by 168
Martin, B., Paesmans, M., Berghmans, T., Branle, F., Ghisdal, L., Mascaux, C., Meert, A.-P., Steels, E., Vallot, F., Verdebout, J.-M., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601095 · Cited by 163
Self-citationPrognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients
Mate, J. L. (1994) · Lung Cancer · doi:10.1016/0169-5002(94)90325-5 · Cited by 156
Fukuyama, Y., Mitsudomi, T., Sugio, K., Ishida, T., Akazawa, K., & Sugimachi, K. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.194 · Cited by 145
Minamoto, T., Mai, M., & Ronai, Z. A. (2000) · PubMed · Cited by 141
c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung
Li, Z. H. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)96453-3 · Cited by 127
Ramírez, J. L., Sarries, C., Castro, P., Roig, B., Queralt, C., Escuín, D., de Aguirre, I., Sánchez, J. M., Manzano, J. L., Vila, M. M., et al. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00740-1 · Cited by 121
The ras Oncogenes in Human Lung Cancer
Rodenhuis, S., & Slebos, R. J. C. (1990) · American Review of Respiratory Disease · doi:10.1164/ajrccm/142.6_pt_2.s27 · Cited by 118
Meert, A., Martin, B., Paesmans, M., Berghmans, T., Mascaux, C., Verdebout, J., Delmotte, P., Lafitte, J.-J., & Jp, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601252 · Cited by 111
Self-citationPrognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
Hommura, F., Dosaka‐Akita, H., Mishina, T., Nishi, M., Kojima, T., Hiroumi, H., Ogura, S., Shimizu, M., Katoh, H., & Kawakami, Y. (2000) · PubMed · Cited by 110
Dingemans, A. C., Witlox, A. M. A., Stallaert, R. A. L. M., van der Valk, P., Postmus, P. E., & Giaccone, G. (1999) · PubMed · Cited by 109
Do Molecular Markers Predict Survival in Non–Small-Cell Lung Cancer?
Greatens, T. M., Niehans, G. A., Rubins, J. B., Jessurun, J., Kratzke, R. A., Maddaus, M. A., & Niewoehner, D. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707108 · Cited by 104
Clinical Significance of p21 Expression in Non–Small-Cell Lung Cancer
Shoji, T., Tanaka, F., Takata, T., Yanagihara, K., Otake, Y., Hanaoka, N., Miyahara, R., Nakagawa, T., Kawano, Y., Ishikawa, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.147 · Cited by 100
Rodenhuis, S., Boerrigter, L., Top, B., Slebos, R. J. C., Mooi, W. J., Veer, L. V., & van Zandwijk, N. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.285 · Cited by 92
Dosaka‐Akita, H., Hu, S., Fujino, M., Harada, M., Kinoshita, I., Xu, H., Kuzumaki, N., Kawakami, Y., & Benedict, W. F. (1997) · PubMed · Cited by 91
p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.
Komiya, T., Hosono, Y., Hirashima, T., Masuda, N., Yasumitsu, T., Nakagawa, K., Kikui, M., Ohno, A., Fukuoka, M., & Kawase, I. (1997) · PubMed · Cited by 89
Schneider, P. M., Praeuer, H. W., Stoeltzing, O., Boehm, J., Manning, J. T., Metzger, R., Fink, U., Wegerer, S., Hoelscher, A. H., & Roth, J. A. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1287 · Cited by 81
Grossi, F., Loprevite, M., Chiaramondia, M., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00232-6 · Cited by 78
Prognostic value of specific KRAS mutations in lung adenocarcinomas.
Siegfried, J. M., Gillespie, A. T., Mera, R. M., Casey, T. J., Keohavong, P., Testa, J. R., & Hunt, J. D. (1997) · PubMed · Cited by 77
Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang, C., Taki, T., Adachi, M., Konishi, T., Higashiyama, M., Kinoshita, M., Hadama, T., & Miyake, M. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.3.553 · Cited by 72
A novel molecular staging protocol for non-small cell lung cancer
Miyake, M., Adachi, M., Huang, C., Higashiyama, M., Kodama, K., & Taki, T. (1999) · Oncogene · doi:10.1038/sj.onc.1202556 · Cited by 60
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.
Volm, M., Koomägi, R., Mattern, J., & Efferth, T. (2002) · PubMed · Cited by 59
Trimodality treatment in Stage III nonsmall cell lung carcinoma
Broermann, P., Junker, K., Brandt, B., et al. (2002) · Cancer · doi:10.1002/cncr.10387 · Cited by 54
Molecular staging of non-small cell lung cancer according to K-ras genotypes.
Rosell, R., Monzó, M., Pifarré, À., Ariza, A., Sánchez, J. J., Moreno, I., Maurel, J., López, M. P., Abad, A., & de Anta, J. M. (1996) · PubMed · Cited by 51
Molecular and biological factors in the prognosis of non-small cell lung cancer
Kanters, S., Lammers, J. J., & Voest, E. E. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081389 · Cited by 45
Wang, Y., Lee, H.-S., Chen, S.-K., Yang, S.-C., & Chen, C. (1998) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050208 · Cited by 36
Rosell, R., Molina, F., Moreno, I., Martínez, E., Pifarré, À., Pous, A. F., Li, S., Skacel, Z., Gómez‐Codina, J., Camps, C., et al. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00421-v · Cited by 24
Kang, Y. H., Kim, K. S., Yu, Y. K., Lim, S., Kim, Y. C., & Park, K. O. (2001) · Journal of Korean Medical Science · doi:10.3346/jkms.2001.16.4.417 · Cited by 11
PROGNOSTIC VALUE OF ONCOPROTEINS FOR THE SURVIVAL OF PATIENTS WITH NONSMALL CELL LUNG CARCINOMAS
Volm, M., Drings, P., Mattern, J., et al. (1993) · International Journal of Oncology · doi:10.3892/ijo.2.5.767 · Cited by 9
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
Nose, H., Imazeki, F., Ohto, M., & Omata, M. (1993) · Cancer · doi:10.1002/1097-0142(19930715)72:2
Cited by
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Self-citationNon-small-cell lung cancers: a heterogeneous set of diseases
Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3775 · Cited by 1,942
Lung cancer in never smokers — a different disease
Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2190 · Cited by 1,608
Evaluation of the Quality of Prognosis Studies in Systematic Reviews
Hayden, J. A., Côté, P., & Bombardier, C. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200603210-00010 · Cited by 1,452
Metadata
- Authors
- Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noel, S., Lafitte, J.-J., & Sculier, J.-P.
- Venue
- British Journal of Cancer
- Published
- 2004-12-14
- Volume
- 92
- Issue
- 1
- Pages
- 131-139
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1991874467
- Cited by
- 605
- References
- 47
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.